Garching / Munich, Germany, November 10, 2025 – (ITM), a prominent radiopharmaceutical biotech company, today announced its participation in several upcoming industry investor conferences and events. ITM’s Chief Executive Officer, Dr. Andrew Cavey, is slated to engage in virtual fireside chats at the William Blair Virtual Radiopharma Conference and during a separate session hosted by Brookline Capital Markets. Furthermore, Dr. Cavey, accompanied by ITM’s Chief Financial Officer, Dr. Klaus Maleck, will be present at the Jefferies London Healthcare Conference 2025.
Event Schedule:
November 13, 2025: William Blair Virtual Radiopharma Conference:
- Dr. Cavey will participate in a virtual fireside discussion at 11:00 am ET / 5:00 pm CET.
November 17 – 19, 2025: Jefferies London Healthcare Conference 2025:
- Dr. Cavey and Dr. Maleck will be accessible for one-on-one meetings with conference attendees.
December 16, 2025: Brookline Capital Markets Fireside Chat (Virtual):
- Dr. Cavey will engage in a virtual fireside discussion at 9:00 am ET / 3:00 pm CET.
For additional information, please reach out to:
ITM Investor Relations
Ben Orzelek
Phone: +49 89 329 8986 1009
Email:
ITM Corporate Communications
Kathleen Noonan/Julia Westermeir
Phone: +49 89 329 8986 1500
Email:
About ITM Isotope Technologies Munich SE
ITM, a leading radiopharmaceutical biotech company, is dedicated to delivering a new generation of radiopharmaceutical treatments and diagnostics for tumors that are difficult to treat. Our goal is to fulfill the requirements of cancer patients, clinicians, and our collaborators through excellence in the development, manufacturing, and global provision of medical radioisotopes. With enhanced patient benefit serving as the core principle for all our endeavors, ITM advances an extensive precision oncology pipeline, which includes multiple phase 3 studies, by combining the company’s high-quality radioisotopes with a variety of targeting molecules. Leveraging our two decades of pioneering radiopharma expertise, central position within the industry, and established global network, ITM aims to provide patients with more effective targeted therapy to improve clinical outcomes and quality of life.
Supplemental Material
